Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 3/20 | 0.53 |
| ▸ | BRD4 | O60885 | 4/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23652894 | 0.84 | TGM2 (0.53) | TGM2BRD4MAPK3ALDH1A1CYP2C19 | |
| SCHEMBL22807505 | 0.84 | TGM2 (0.53) | TGM2BRD4MAPK3ALDH1A1CYP2C19 | |
| SCHEMBL17522184 | 0.83 | TGM2 (0.49) | TGM2BRD4MAPK3ALDH1A1CYP2C19 | |
| SCHEMBL17524715 | 0.82 | TGM2 (0.54) | TGM2MAPK3ALDH1A1CYP2C19 | |
| SCHEMBL8549226 | 0.81 | ALDH1A1 (0.66) | TGM2ALDH1A1CYP2C19EGFRHTT | |
| SCHEMBL29505769 | 0.81 | ALDH1A1 (0.66) | TGM2ALDH1A1CYP2C19EGFRHTT | |
| SCHEMBL18764924 | 0.81 | TGM2 (0.58) | TGM2ALDH1A1CYP2C19EGFRHTT | |
| SCHEMBL29505767 | 0.81 | TGM2 (0.58) | TGM2ALDH1A1CYP2C19EGFRHTT | |
| SCHEMBL17443389 | 0.80 | TGM2 (0.56) | TGM2MAPK3ALDH1A1CYP2C19EGFR | |
| SCHEMBL26092148 | 0.80 | HTT (0.45) | ALDH1A1CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2020-04-14 | — | — | US | disclosed |
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-18 | — | — | US | disclosed |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-21 | — | — | US | disclosed |
| US-9663524-B2 | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors | CELGENE CAR LLC (BM) | 2017-05-30 | — | — | US | disclosed |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | TGM2 2445/4885BRD4 813/4885MAPK3 341/4885 |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | TGM2 2445/4885BRD4 813/4885MAPK3 341/4885 |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | PDXK, DCK, DTYMK | TGM2 3342/4885BRD4 884/4885MAPK3 123/4885 |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | TGM2 2445/4885BRD4 813/4885MAPK3 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.